



RECEIVED
JUN 05 2001

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/200,743
Filing Date	Nov. 30, 1998
First Named Inventor	Benneker et al.
Group Art Unit	1625
Examiner Name	Chang, C.
Attorney Docket Number	POT-010US.2

Total Number of Pages in This Submission **4**

ENCLOSURES (check all that apply)

- | | | |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input checked="" type="checkbox"/> Amendment / Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input type="checkbox"/> Other Enclosure(s) (please identify below): |
|---|---|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name
Mark R. Buscher

Signature

Mark R. Buscher

Date

5/29/01

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: **May 29, 2001**

Typed or printed name
Mark R. Buscher

Signature

Mark R. Buscher

Date

5/29/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

JUN 05 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re application of:

BENNEKER et al.

Appl. No.: 09/200,743

Filed: November 30, 1998

For: CRYSTALLINE PAROXETINE
METHANE SULFONATE (as amended)

Art Unit: 1625

Examiner: Chang, C.

P. TUCK
2/C
6/6/01

AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

May 29, 2001
(Tuesday after
Monday Holiday)

Sir:

In response to the Restriction Requirement set forth in the Office Letter dated April 26, 2001, the following amendment and remarks are respectfully submitted in connection with the above-identified application.

In The Claims

Please cancel claim 39 without prejudice or disclaimer of the subject matter thereof.

REMARKS

The Examiner in charge of the above-identified application has required restriction between the following groups of claims:

Group I: Claims 30-38, directed to crystalline paroxetine methane sulfonate, compositions thereof, and methods of using the same; and